Intermediate molecular weight proteinuria and albuminuria identify scleroderma patients with increased morbidity

Clinical Nephrology

Volumn 70, Issue 2, 2008, Pages 110-117

  Seiberlich, B ^a   Hunzelmann, N ^b   Krieg, T ^b   Weber, M ^a   Schulze Lohoff, E ^a,c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Marien Hospital   (Germany)

Author keywords

Albuminuria; Renal crisis; Scleroderma; Systemic sclerosis; Urine electrophoresis

Indexed keywords

AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CHLOROQUINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ADULT; AGED; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; DIFFUSE SCLERODERMA; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INTERMEDIATE MOLECULAR WEIGHT PROTEINURIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; PROTEINURIA; SCLERODERMA; SYSTEMIC SCLEROSIS; SYSTOLIC BLOOD PRESSURE; URINALYSIS; URINARY EXCRETION; VASCULAR DISEASE;

EID: 48749102252     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp70110     Document Type: Article

References (31)

1. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004; 351: 1285-1295.
2. Anders HJ, Wiebecke B, Haedecke C, Sanden S, Combe C, Schlondorff D. MPO-ANCA-positive crescentic glomerulonephritis: a distinct entity of scleroderma renal disease? Am J Kidney Dis. 1999; 33: 3-4.
3. Bryan C, Knight C, Black AM, Silman SJ. Prediction of five-year survival following presentation with scleroderma. Arthritis Rheum. 1999; 42: 2660-2665.
4. Cannon PJ, Hassar M, Case DB et al. The relationship of hypertension and renal failure in scleroderma to structural and functional abnormalities of the renal cortical circulation. Medicine. 1974; 53: 1-46.
5. Cockcroft D, Gault MD. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
6. Dawnay A, Wilson AG, Lamb E et al. Microalbuminuria in systemic sclerosis. Ann Rheum Dis. 1992; 51: 384-388.
7. Donohoe JF. Scleroderma and the kidney. Kidney Int. 1992; 41: 462-477.
8. Francois B, Moulin G, Assenat H et al. The kidney in systemic scleroderma. A report of 38 consecutive cases. Nephrologie. 1982; 3: 85-91.
9. Gliddon AE, Dore CJ, Black CM et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 2007; 56: 3837-3846.
10. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardio-vascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-1305.
11. Gross O, Beirowski B, Koepke ML, Kuck J, Rainer M, Addicks K, Smyth N, Schulze-Lohoff E, Weber M. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int. 2003; 63: 438-446.
12. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE, Prevention of Renal and Vascular End-Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002; 106: 1777-1782.
13. Hillis GS, Khan IH, Simpson JG, Rees AJ. Scleroderma, D-penicillamine treatment, and progressive renal failure associated with positive antimyeloperoxidase antineutrophil cytoplasmic antibodies. Am J Kidney Dis. 1997; 30: 279-281.
14. 1 microglobulin as a marker of nephropathy in Type 2-diabetic Asian subjects in Singapore. Diabetes Care. 2003; 26: 338-342.
15. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med. 2004; 351: 1344-1346.
16. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death idependently of renal function, hypertension and diabetes. Circulation. 2004; 110: 32-35.
17. Koliakos G, Papachristou F, Papadopoulou M et al. Electrophoretic analysis of urinary proteins in diabetic adolescents. J Clin Lab Anal. 2001; 15: 178-183.
18. LeRoy EC, Black C, Fleischmaier R, Jablonska S, Krieg T et al. Scleroderma systemic sclerosis: classification subsets and pathogenesis. J Rheumatol. 1988; 15: 202-205.
19. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329: 1456-1462.
20. Norgaard K, Jensen T, Feldt-Rasmussen B. Transcapillary escape rate of albumin in hypertensive patients with Type 1 diabetes mellitus. Diabetologia. 1993; 36: 57-61.
21. Parving HH, Lehnert H, Brochner-Mortenson J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: the effects of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl J Med. 2001; 345: 870-878.
22. Rhew EY, Barr WG. Scleroderma renal crisis. Cuff Rheumatol Rep. 2004; 6: 129-136.
23. Ritz E. Albuminuria and vascular damage - the vicious twins. N Engl J Med. 2003; 348: 2349-2352.
24. Steen VD, Medsger TA, Osial TA Jr et al. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med. 1984; 76: 779-786.
25. Steen VD, Constantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin-converting enzyme (ACE) inhibitors. Ann Intern Med. 1990; 113: 352-357.
26. Steen VD, Mayes MD, Merkel PA. Assessment of kidney involvement. Clin Exp Rheumatol. 2003; 21: S29-S31.
27. Steen VD, Syzd A, Johnson JP et al. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol. 2005; 32: 649-655.
28. 2-microglobulin in patients with Balkan nephropathy and in healthy members of their families. Kidney Int. 1991; 34: S21-S26.
29. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980; 23: 581-590.
30. Traub YM, Shapiro AP, Rodnan GP et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore). 1983; 62: 335-352.
31. Wartha R, Nebinger D, Gekle D. Low-molecular weight proteinuria in diabetic children: a marker of early diabetic nephropathy? Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985; 21: 638-641.